BD Veritor™ Plus System
for Rapid Detection of RSV
Simple RSV testing for those at highest risk.
The portable, easy-to-use BD Veritor™ Plus System for Rapid Detection of RSV provides reliable results in 10 minutes.
When your pediatric patients† need fast, reliable RSV testing, turn to the BD Veritor™ Plus System. Offering reliable results at point of care in a simple-to-operate, handheld instrument.
BD Veritor™ Plus System for Rapid Detection of RSV (CLIA-waived kit) offers proven performance
| PPA† | NPA‡ | Results in |
Compared to viral culture | 91.8% (95% CI: 85.9%, 95.4%) | 93.3% (95% CI: 90.4%, 94.4%) |
10 minutes
|
Compared to PCR | 81.6% (95% CI: 75.2%, 86.6%) | 99.1% (95% CI: 97.5%, 99.7%) | 10 minutes |
†positive percent agreement
‡negative percent agreement
Ordering information | Cat no. | Qty |
BD Veritor™ Plus System RSV CLIA-waived kit | 256038 | 30 tests |
BD Veritor™ Plus System RSV moderately complex kit | 256042 | 30 tests |
BD Veritor™ Plus Analyzer | 256066 | 1 unit |
†The BD Veritor™ RSV CLIA-waived kit is indicated for use in patients under 6 years of age. The BD Veritor™ RSV moderately complex kit is individual for use in patients under 20 years of age.
Get more answers with every sample.
Simplifies the testing process
- Easy operation and single-button functionality may help reduce potential manual errors
- Provides intuitive sample processing with prefilled, unitized tubes
Delivers workflow efficiency
Adapts easily to your workflow by offering 2 operational modes
- Walk Away: the test device is inserted into the Analyzer immediately after preparation, allowing staff to multitask while the sample incubates
- Analyze Now: the test device is inserted after the incubation time is complete, allowing batches of samples to be tested at once
Option to test the same sample with a BD Veritor™ Flu A+B test device1
Provides results traceability
- Downloadable test records matched to kit lot number, operator, patient, or specimen ID with the BD Veritor™ InfoWiFi module or via the companion ImageMover application
- Offers result printing capabilities via USB port
Achieves reliable, rapid results
- Displays easy-to-read digital results for RSV in 10 minutes1
- Provides clear, objective results by correcting for nonspecific binding and detecting faint lines not recognized by the unaided eye2
Contact a Sales Representative to get your organization’s
diagnostic testing program started today
How It Works
The BD Veritor™ Plus System provides an easy sample-collection process that can be incorporated across a variety of clinical settings.
Step 1: Collect sample
Step 2: Mix the swab with the reagent vial
Step 3: Prepare assay with the sample
Step 4: Run the test
Step 5: Insert the cartridge and read the results
BD Veritor™ Plus System Support & Training
See how BD supports you with tools, education, and training—enabling a streamlined point-of-care experience for those you serve, and confidence in your results.
Professional Care Testing
The BD Veritor™ Plus System enhances point-of-care testing for COVID-19, Flu A+B, COVID-19 & Flu A+B,* RSV and Group A Strep, providing rapid diagnostic testing in a convenient, portable instrument.
1. BD Veritor™ System for Rapid Detection of Respiratory Syncytial Virus (RSV), package insert, 8086098. Franklin Lakes, NJ: Becton, Dickinson and Company BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663
*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
BD, the BD Logo, and BD Veritor are trademarks of Becton, Dickinson and Company or its affiliates. © 2025 BD. All rights reserved.
bd.com